Key Record Dates
| ClinicalTrials.gov Identifier: | NCT01968551 |
|---|---|
| Brief Title: | Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults |
| First Submitted : | September 26, 2013 |
| First Submitted that Met QC Criteria : | October 18, 2013 |
| First Posted : | October 24, 2013 (Estimate) |
| Results First Submitted : | July 20, 2016 |
| Results First Submitted that Met QC Criteria : | September 14, 2016 |
| Results First Posted : | November 1, 2016 (Estimate) |
| Certification/Extension First Submitted : | April 16, 2015 |
| Certification/Extension First Submitted that Met QC Criteria : | April 16, 2015 |
| Certification/Extension First Posted : | May 6, 2015 (Estimate) |
| Last Update Submitted that Met QC Criteria : | July 7, 2017 |
| Last Update Posted : | August 14, 2017 |